WO2005116067A3 - Conjugues tripeptidiques agonistes de la msh - Google Patents

Conjugues tripeptidiques agonistes de la msh Download PDF

Info

Publication number
WO2005116067A3
WO2005116067A3 PCT/FR2005/001165 FR2005001165W WO2005116067A3 WO 2005116067 A3 WO2005116067 A3 WO 2005116067A3 FR 2005001165 W FR2005001165 W FR 2005001165W WO 2005116067 A3 WO2005116067 A3 WO 2005116067A3
Authority
WO
WIPO (PCT)
Prior art keywords
acid
unsaturations
general formula
phe
msh
Prior art date
Application number
PCT/FR2005/001165
Other languages
English (en)
Other versions
WO2005116067A2 (fr
Inventor
Jean Martinez
Pascal Verdie
Pascaline Dubs
Anne-Marie Pinel
Gilles Subra
Original Assignee
Centre Nat Rech Scient
Inst Europeen Biolog Cellulair
Univ Montpellier I
Univ Montpellier Ii
Jean Martinez
Pascal Verdie
Pascaline Dubs
Anne-Marie Pinel
Gilles Subra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0405069A external-priority patent/FR2870242B1/fr
Application filed by Centre Nat Rech Scient, Inst Europeen Biolog Cellulair, Univ Montpellier I, Univ Montpellier Ii, Jean Martinez, Pascal Verdie, Pascaline Dubs, Anne-Marie Pinel, Gilles Subra filed Critical Centre Nat Rech Scient
Priority to ES05770969.3T priority Critical patent/ES2456090T3/es
Priority to JP2007512281A priority patent/JP4897970B2/ja
Priority to US11/596,041 priority patent/US8017581B1/en
Priority to EP05770969.3A priority patent/EP1745071B1/fr
Priority to CA002565805A priority patent/CA2565805A1/fr
Publication of WO2005116067A2 publication Critical patent/WO2005116067A2/fr
Publication of WO2005116067A3 publication Critical patent/WO2005116067A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne un conjugué tripeptidique répondant à la formule générale I A-AA1­AA2-AA3-NH2 dans laquelle A représente le radical correspondant à un acide monocarboxylique de formule générale II HOOC-R dans laquelle R représente un radical aliphatique en C1-C24, linéaire ou ramifié, éventuellement substitué par un groupe hydroxyle, pouvant comporter une ou plusieurs insaturations, avantageusement de 1 à 6 insaturations, l'acide lipoïque ou sa forme réduite l'acide dihydrolipoïque, la N-lipoyl-lysine, ou l'acide phénylbutyrique, AA1, AA2 et AA3 identiques ou différents représentent indépendamment l'un de l'autre un acide aminé choisi parmi His, Phe, Ala, Arg, Lys, Orn, Trp, Nap, Tpi et Tic, à la condition qu'au moins l'un des AA1, AA2 ou AA3 représente Phe, avantageusement DPhe sous forme d'énantiomères ou de diastéréoisomères ainsi que leurs mélanges, y compris les mélanges racémiques.
PCT/FR2005/001165 2004-05-11 2005-05-10 Conjugues tripeptidiques agonistes de la msh WO2005116067A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
ES05770969.3T ES2456090T3 (es) 2004-05-11 2005-05-10 Conjugados tripeptídicos agonistas de la MSH
JP2007512281A JP4897970B2 (ja) 2004-05-11 2005-05-10 Ｍｓｈのアゴニストであるトリペプチド複合体
US11/596,041 US8017581B1 (en) 2004-05-11 2005-05-10 MSH-agonist tripeptide conjugates
EP05770969.3A EP1745071B1 (fr) 2004-05-11 2005-05-10 Conjugues tripeptidiques agonistes de la msh
CA002565805A CA2565805A1 (fr) 2004-05-11 2005-05-10 Conjugues tripeptidiques agonistes de la msh

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0405069 2004-05-11
FR0405069A FR2870242B1 (fr) 2004-05-11 2004-05-11 Peptides ou conjugues peptidiques derives de la msh et leur utilisation dans le traitement cosmetique de la canitie.
FR0411276 2004-10-22
FR0411276A FR2870243B1 (fr) 2004-05-11 2004-10-22 Conjugues tripeptidiques agonistes de la msh

Publications (2)

Publication Number Publication Date
WO2005116067A2 WO2005116067A2 (fr) 2005-12-08
WO2005116067A3 true WO2005116067A3 (fr) 2006-06-08

Family

ID=35451453

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2005/001165 WO2005116067A2 (fr) 2004-05-11 2005-05-10 Conjugues tripeptidiques agonistes de la msh

Country Status (7)

Country Link
US (1) US8017581B1 (fr)
EP (1) EP1745071B1 (fr)
JP (1) JP4897970B2 (fr)
CA (1) CA2565805A1 (fr)
ES (1) ES2456090T3 (fr)
FR (1) FR2870243B1 (fr)
WO (1) WO2005116067A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8507649B2 (en) 2006-05-05 2013-08-13 Sederma Cosmetic compositions comprising at least one peptide with at least one immobilized aromatic cycle

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102387772A (zh) * 2008-05-29 2012-03-21 唐纳德·欧文 皮肤美容组合物中的寡聚生物表面活性剂
US8541361B2 (en) 2009-04-22 2013-09-24 Dsm Ip Assets B.V. Composition
WO2014195850A2 (fr) * 2013-06-05 2014-12-11 Mahesh Kandula Compositions et méthodes de traitement de maladies neurologiques et de troubles neurologiques
BR112019005069A2 (pt) * 2016-09-15 2019-06-04 Dsm Ip Assets Bv compostos inovadores
WO2021059266A1 (fr) * 2019-09-26 2021-04-01 S.I.S. Shulov Innovative Science Ltd. Compositions anti-âge et leurs procédés d'utilisation
FR3112478B1 (fr) 2020-07-15 2022-12-02 France Cosmephyl Lab Nouvelles compositions associant des dérivés de chanvre et au moins un peptide et leur utilisation

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995008564A1 (fr) * 1993-09-22 1995-03-30 Institut Europeen De Biologie Cellulaire DERIVES PEPTIDIQUES DE L'α-MSH ET LEUR APPLICATION
WO1998025584A2 (fr) * 1996-12-12 1998-06-18 Lancaster Group Gmbh Preparation cosmetique avec additif peptidique
FR2810323A1 (fr) * 2000-06-16 2001-12-21 Shiseido Int France Utilisation cosmetique d'un lipopeptide
WO2001098362A2 (fr) * 2000-06-16 2001-12-27 Hercules Incorporated Peptides modifies chimiquement, compositions et leur procede de production et d'utilisation
WO2004099237A1 (fr) * 2003-05-08 2004-11-18 Pentapharm Ag Tripeptides et leurs derives utilises en cosmetique pour ameliorer la structure de la peau
WO2005116068A1 (fr) * 2004-05-11 2005-12-08 Institut Europeen De Biologie Cellulaire Peptides ou conjugues peptidiques derives de la msh et leur utilisation dans le traitement cosmetique de la canitie

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674839A (en) 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
US5786332A (en) 1995-03-06 1998-07-28 Trega Biosciences, Inc. Cytokine restraining agents and methods of use in pathologies and conditions associated with altered cytokine levels
US6054556A (en) 1995-04-10 2000-04-25 The Arizona Board Of Regents On Behalf Of The University Of Arizona Melanocortin receptor antagonists and agonists
FR2781157B1 (fr) 1998-07-15 2000-08-25 Oreal Composition anti-inflammatoire
US6911447B2 (en) 2001-04-25 2005-06-28 The Procter & Gamble Company Melanocortin receptor ligands
FR2835528B1 (fr) 2002-02-01 2004-03-12 Inst Europ Biolog Cellulaire Nouveaux derives peptidiques, leur preparation et leur application therapeutique et cosmetique
US20040010010A1 (en) 2002-04-30 2004-01-15 Ebetino Frank Hallock Melanocortin receptor ligands
US7034004B2 (en) 2002-05-07 2006-04-25 University Of Florida Peptides and methods for the control of obesity
EP1633380A4 (fr) * 2003-06-19 2010-08-11 Yeda Res & Dev Lipopeptides antimicrobiens et anticancereux

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995008564A1 (fr) * 1993-09-22 1995-03-30 Institut Europeen De Biologie Cellulaire DERIVES PEPTIDIQUES DE L'α-MSH ET LEUR APPLICATION
WO1998025584A2 (fr) * 1996-12-12 1998-06-18 Lancaster Group Gmbh Preparation cosmetique avec additif peptidique
FR2810323A1 (fr) * 2000-06-16 2001-12-21 Shiseido Int France Utilisation cosmetique d'un lipopeptide
WO2001098362A2 (fr) * 2000-06-16 2001-12-27 Hercules Incorporated Peptides modifies chimiquement, compositions et leur procede de production et d'utilisation
WO2004099237A1 (fr) * 2003-05-08 2004-11-18 Pentapharm Ag Tripeptides et leurs derives utilises en cosmetique pour ameliorer la structure de la peau
WO2005116068A1 (fr) * 2004-05-11 2005-12-08 Institut Europeen De Biologie Cellulaire Peptides ou conjugues peptidiques derives de la msh et leur utilisation dans le traitement cosmetique de la canitie

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
AL-OBEIDI F ET AL: "Synthesis and biological activities of fatty acid conjugates of a cyclic lactam alpha-melanotropin", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 35, 1992, pages 118 - 123, XP002244695, ISSN: 0022-2623 *
HADLEY M E ET AL: "BIOLOGICAL ACTIVITIES OF MELANOTROPIC PEPTIDE FATTY ACID CONJUGATES", PIGMENT CELL RESEARCH, MUNKSGAARD INTERNATIONAL PUBLISHERS, CAMBRIDGE, MA, DK, vol. 4, no. 4, October 1991 (1991-10-01), pages 180 - 185, XP008046422, ISSN: 0893-5785 *
HASKELL-LUEVANO C ET AL: "Characterization of melanocortin NDP-MSH agonist peptide fragments at the mouse central and peripheral melanocortin receptors", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 44, no. 13, 2001, pages 2247 - 2252, XP002970859, ISSN: 0022-2623 *
HASKELL-LUEVANO C ET AL: "Discovery of prototype peptidomimetic agonists at the human melanocortin receptors MC1R and MC4R.", JOURNAL OF MEDICINAL CHEMISTRY. 4 JUL 1997, vol. 40, no. 14, 4 July 1997 (1997-07-04), pages 2133 - 2139, XP002084110, ISSN: 0022-2623 *
HASKELL-LUEVANO C ET AL: "Truncation studies of alpha-melanotropin peptides identify tripeptide analogues exhibiting prolonged agonist bioactivity", PEPTIDES, ELMSFORD, US, vol. 17, no. 6, 1996, pages 995 - 1002, XP002970858, ISSN: 0196-9781 *
HOLDER J R ET AL: "Characterization of aliphatic, cyclic, and aromatic N-terminally capped His-D-Phe-Arg-Trp-NH2 tetrapeptides at the melanocortin receptors", EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, NL, vol. 462, 21 February 2003 (2003-02-21), pages 41 - 52, XP002263329, ISSN: 0014-2999 *
HRUBY V J ET AL: "ALPHA-MELANOTROPIN: THE MINIMAL ACTIVE SEQUENCE IN THE FROG SKIN BIOASSAY", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 30, no. 11, 1987, pages 2126 - 2130, XP001146488, ISSN: 0022-2623 *
TODOROVIC ALEKSANDAR ET AL: "N-terminal fatty acylated His-DPhe-Arg-Trp-NH2 tetrapeptides: Influence of fatty acid chain length on potency and selectivity at the mouse melanocortin receptors and human melanocytes", JOURNAL OF MEDICINAL CHEMISTRY, vol. 48, no. 9, May 2005 (2005-05-01), pages 3328 - 3336, XP002375935, ISSN: 0022-2623 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8507649B2 (en) 2006-05-05 2013-08-13 Sederma Cosmetic compositions comprising at least one peptide with at least one immobilized aromatic cycle

Also Published As

Publication number Publication date
JP4897970B2 (ja) 2012-03-14
FR2870243A1 (fr) 2005-11-18
JP2008502599A (ja) 2008-01-31
US8017581B1 (en) 2011-09-13
EP1745071A2 (fr) 2007-01-24
ES2456090T3 (es) 2014-04-21
FR2870243B1 (fr) 2010-11-19
CA2565805A1 (fr) 2005-12-08
EP1745071B1 (fr) 2014-03-12
WO2005116067A2 (fr) 2005-12-08

Similar Documents

Publication Publication Date Title
WO2005116067A3 (fr) Conjugues tripeptidiques agonistes de la msh
WO2005116068A8 (fr) Peptides ou conjugues peptidiques derives de la msh et leur utilisation dans le traitement cosmetique de la canitie
WO2005115174A3 (fr) Conjugues dipeptidiques antagonistes de l’alpha-msh
BRPI0514420A (pt) peptìdeo, variante do mesmo, ou um sal farmaceuticamente aceitável do mesmo, composição, uso de um peptìdeo ou de uma variante de peptìdeo, substrato, e, métodos de tratamento ou prevenção de um infecção microbiana, e de tratamento de uma ferida em um indivìduo
TW200716589A (en) Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]-oxepino [4,5-c] pyrrole
ATE533765T1 (de) Pyrroloä2,3-cüpyridinderivate und verfahren für deren herstellung
ID25979A (id) TURUNAN-TURUNAN KOMTOTESIN (Pecahan dari P-963785)
FR2820141B1 (fr) Composition transparente a base de polyamide
UA93666C2 (en) Conjugates of insulin-like growth factor-1 (igf-1) and poly(ethylene glycol)
IS6371A (is) Ný heterósýklísk efnasambönd og notkun þeirra semlyf
WO2005021494A3 (fr) Peptides d'acides amines d
WO2006017180A3 (fr) Dimeres de glycopeptide et leurs utilisations
WO2007025988A3 (fr) Formulations liquides d'hormone de croissance pegylee
HK1105977A1 (en) Pyrrolo [3,2-c] pyridine derivatives and processes for the preparation
WO2001072263A3 (fr) Utilisation d'ectoine ou de derives d'ectoine pour proteger la proteine du stress de la peau
Kobayashi et al. Synthesis of N-kojic-amino acid and N-kojic-amino acid-kojiate and their tyrosinase inhibitory activity
WO2004040262A3 (fr) Compositions et procedes pour modifier les effets toxiques de composes proteiques
AU2003235283A1 (en) Gamma-secretase inhibitors
WO2002020017A3 (fr) Utilisation de l'ectoine ou de derives de l'ectoine pour la stabilisation du p53
ATE475663T1 (de) Lamellarinanaloga mit antitumorwirkung
CA2379696A1 (fr) Inhibition de l'absorption renale de molecules pouvant potentiellement endommager les reins
EP1762273A3 (fr) Composition cosmétique gommante
ATE466013T1 (de) Pyrroloä3,2-cüpyridinderivate und verfahren zu deren herstellung
JP2003510257A5 (fr)
WO2005054303A8 (fr) Dimères de cyclodextrines et leurs dérivés, leurs procédés de préparation et leur utilisation notamment pour la solubilisation de substances pharmacologiquement actives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2565805

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007512281

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005770969

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005770969

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11596041

Country of ref document: US